10 Spam-Free Article(s) Found
Article Searches
Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review http://www.zacks.com/stock/news/876410/regenerons-bla-for-ebola-vaccine-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-876410 Apr 17, 2020 - The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Earnings Data Deluge http://www.zacks.com/stock/news/893984/earnings-data-deluge?cid=CS-ZC--economic_highlights-893984 Apr 28, 2020 - Earnings Data Deluge
Merck & Co Inc (MRK) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/04/28/merck-co-inc-mrk-q1-2020-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 28, 2020 - MRK earnings call for the period ending March 31, 2020.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre http://www.zacks.com/stock/news/880319/incyte-gets-fda-nod-for-cholangiocarcinoma-drug-pemazyre?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-880319 Apr 20, 2020 - Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales http://www.zacks.com/stock/news/880340/growth-in-new-drugs-to-give-a-boost-to-roche-rhhby-q1-sales?cid=CS-ZC-FT-analyst_blog|earnings_preview-880340 Apr 20, 2020 - Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase? http://www.zacks.com/stock/news/887532/will-pfizers-pfe-biopharma-unit-q1-earnings-increase?cid=CS-ZC-FT-analyst_blog|earnings_preview-887532 Apr 24, 2020 - In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS http://www.zacks.com/stock/news/891794/big-drug-stock-q1-earnings-due-on-apr-28-mrk-pfe-and-nvs?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-891794 Apr 27, 2020 - Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
A Plethora of Q1 Earnings Results: MMM, CAT, PEP & More http://www.zacks.com/stock/news/893951/a-plethora-of-q1-earnings-results-mmm-cat-pep-more?cid=CS-ZC-FT-ahead_of_wall_street-893951 Apr 28, 2020 - A big morning for Q1 earnings reports joins a new Advance Trade in Goods report out this morning. Pre-market indexes are way in the green at this hour.
Merck & Co., Inc. (MRK) CEO Ken Frazier on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4340675-merck-co-inc-mrk-ceo-ken-frazier-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare Apr 28, 2020 - Merck & Co., Inc. (NYSE:MRK) Q1 2020 Results Earnings Conference Call April 28, 2020 08:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Ken Frazier - Chairman a
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/911521/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-911521 May 01, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pages: 1

Page 1